Topic: Amyloid, tau and blood-test diagnosis
ADAM10 plays a fundamental role in brain function, and sufficient studies support its involvement in AD pathogenesis. There are only isolated examples of ADAM10 mutations as a genetic cause, but these encourage continued screening in familial AD. ADAM10 levels in platelets could be considered as a biomarker. The enhancement of ADAM10 expression in AD remains a therapeutic target that requires further research.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Agüero, P., & Tortosa, E. G. (2026). ADAM10 and its role in Alzheimer disease. Neurología (English Edition). https://doi.org/10.1016/j.nrleng.2026.502083
Vancouver
Agüero P, Tortosa EG. ADAM10 and its role in Alzheimer disease. Neurología (English Edition). 2026. doi:10.1016/j.nrleng.2026.502083. PMID: 42097504.
BibTeX
@article{aguero2026-42097504,
author = {Agüero, Pablo and Tortosa, Estrella Gómez},
title = {{ADAM10 and its role in Alzheimer disease}},
journal = {Neurología (English Edition)},
year = {2026},
doi = {10.1016/j.nrleng.2026.502083},
pmid = {42097504},
url = {https://doi.org/10.1016/j.nrleng.2026.502083}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- ADAM10 plays a fundamental role in brain function, and sufficient studies support its involvement in AD pathogenesis.
- There are only isolated examples of ADAM10 mutations as a genetic cause, but these encourage continued screening in familial AD.
- ADAM10 levels in platelets could be considered as a biomarker.
- The enhancement of ADAM10 expression in AD remains a therapeutic target that requires further research.
Why it matters
This review reports that ADAM10 is involved in Alzheimer disease pathogenesis, though only isolated examples of ADAM10 mutations as a genetic cause exist. It states that enhancing ADAM10 expression remains a therapeutic target that requires further research, and that ADAM10 levels in platelets could be considered a biomarker.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 29/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 28 of the 96 points we could judge it on, which is 29 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurología (English Edition)) |
| Journal's citation record | 0 / 4 | Neurología (English Edition): journal h-index 47 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Estrella Gómez Tortosa holds only 6 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Hospital Universitario Fundación Jiménez Díaz: institution h-index 301 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42097504) |
| Free to read | 2 / 2 | Free to read |
| Points | 28 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 28 of the 96 points we could judge it on is 29 out of 100. |
| Total | 29 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.nrleng.2026.502083
- PubMed: 42097504
- Original source →
- Free full text: Neurología (English Edition) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Related studies in Genetics
Also in Genetics
214 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.